

29 November 2023

ASX Announcement

Nasodine COVID-19 Patent Granted in South Africa

- Patent now granted in US, Australia and South Africa; other countries pending
- Protects the use of Nasodine in reducing the nasal viral load of SARS-CoV-2

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is pleased to announce that its patent covering the use of Nasodine® Nasal Spray (**Nasodine**) in COVID-19 has now been granted in South Africa. The patent has previously been granted in the US and Australia (innovation patent), and acceptance in other countries is still pending.

The patent specifically protects the use of intranasal povidone-iodine as a method of reducing the viral load of SARS-CoV-2 in the nose. Relevantly, the Company recently announced the results of its Phase 2 trial in COVID-19 patients, which demonstrated that Nasodine achieved 100% clearance of the SARS-CoV-2 virus from the nasal passages (refer announcement 7 August 2023).

The Company also recently announced the proposed use of Nasodine in some markets as a nasal antiseptic/disinfectant (refer announcement 15 November 2023).

“This patent is very relevant to that use, which includes the elimination of pathogenic viruses from the nose, such as SARS-CoV-2 and any future pandemic virus,” said Dr Peter Molloy, Executive Chairman of Firebrick.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded in 2012 with the mission to develop and commercialise a povidone-iodine nasal spray (www.firebrickpharma.com). The Company has successfully developed a povidone-iodine nasal spray, called Nasodine® Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the US, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com